secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2025-12-05T23:59:59+00:00
Accession:  0001193125-25-309619
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma receives Nasdaq bid-price deficiency notice; 180 days to cure
-------------------------------------------------------------------------

- On Dec 4, 2025, Nasdaq notified ATYR that its common stock closed below $1.00 for 30 consecutive business days.
- Company has until June 2, 2026 to regain compliance with Nasdaq Listing Rule 5550(a)(2).
- If not cured, may be eligible for a second 180-day period by meeting other initial listing standards.
- Company may consider a reverse stock split if needed to cure the deficiency.
- Failure to regain compliance could lead to delisting and an appeal process.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000119312525309619/0001193125-25-309619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000119312525309619/atyr-20251204.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-309619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer